SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment.

Defeng KongZhenrong YangGuoliang LiQuanyou WuZhaoru GuDuo WanQi ZhangXiaoli ZhangShujun ChengBinlei LiuKaitai ZhangWen Zhang

Published in: BMC medicine (2022)

Our data support the feasibility of oncolytic virus therapy in combination with anti-SIRPα antibodies and suggest a new strategy for oncolytic virus therapy.

Keyphrases

stem cells
signaling pathway
electronic health record
big data
machine learning
disease virus
cell therapy
deep learning